Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sparano

Showing results (91-100 of 655) with videos related to

Pageof 66
Sort By:
Lancet (London, England)|December 29, 2000
Troponins for predicting cardiotoxicity from cancer therapyJ A Sparano, A C Wolff, D Brown
La Clinica Terapeutica|July 31, 1976
[Current views on amenorrhea: diagnostic and therapeutic possibilities]F Fraioli, R Weisz, M Fetonti, et al.
Expert Opinion on Pharmacotherapy|March 1, 2021
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancerSun Young Oh, Shafia Rahman, Joseph A Sparano
Surgical Oncology Clinics of North America|November 28, 2016
Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal CancerChia-Ching J Wang, Joseph Sparano, Joel M Palefsky
NPJ Breast Cancer|April 5, 2023
An emerging generation of endocrine therapies in breast cancer: a clinical perspectiveRima Patel, Paula Klein, Amy Tiersten, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2016
In Regard to Bruner et alNitin Ohri, Shalom Kalnicki, Joseph A Sparano, et al.
Cancer|June 24, 2026
"Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and realityMina S Sedrak, Suresh S Ramalingam, Joseph A Sparano
Human Factors|April 27, 2016
Implicit Coordination Strategies for Effective Team CommunicationAbhizna Butchibabu, Christopher Sparano-Huiban, Liz Sonenberg, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|June 4, 2004
Participation in the academic associate program: effect on medical school admission rateDina M Sparano, Frances S Shofer, Judd E Hollander
Medical Oncology (Northwood, London, England)|October 5, 2006
A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphomaLakshmi Rajdev, Gary Goldberg, Una Hopkins, et al.
Pageof 66

Showing results (91-100 of 655) with videos related to

Sort By:
Pageof 66
Lancet (London, England)|December 29, 2000
Troponins for predicting cardiotoxicity from cancer therapyJ A Sparano, A C Wolff, D Brown
La Clinica Terapeutica|July 31, 1976
[Current views on amenorrhea: diagnostic and therapeutic possibilities]F Fraioli, R Weisz, M Fetonti, et al.
Expert Opinion on Pharmacotherapy|March 1, 2021
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancerSun Young Oh, Shafia Rahman, Joseph A Sparano
Surgical Oncology Clinics of North America|November 28, 2016
Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal CancerChia-Ching J Wang, Joseph Sparano, Joel M Palefsky
NPJ Breast Cancer|April 5, 2023
An emerging generation of endocrine therapies in breast cancer: a clinical perspectiveRima Patel, Paula Klein, Amy Tiersten, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2016
In Regard to Bruner et alNitin Ohri, Shalom Kalnicki, Joseph A Sparano, et al.
Cancer|June 24, 2026
"Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and realityMina S Sedrak, Suresh S Ramalingam, Joseph A Sparano
Human Factors|April 27, 2016
Implicit Coordination Strategies for Effective Team CommunicationAbhizna Butchibabu, Christopher Sparano-Huiban, Liz Sonenberg, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|June 4, 2004
Participation in the academic associate program: effect on medical school admission rateDina M Sparano, Frances S Shofer, Judd E Hollander
Medical Oncology (Northwood, London, England)|October 5, 2006
A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphomaLakshmi Rajdev, Gary Goldberg, Una Hopkins, et al.
Pageof 66